B Bonin, P Vandel, J P Kantelip. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Adrenergic alpha-2 Receptor AgonistsAdrenergic alpha-Agonists/adverse effectsAdrenergic alpha-Agonists/pharmacokineticsAdrenergic alpha-Agonists/therapeutic useAdultAntidepressive Agents, Tricyclic/adverse effectsAntidepressive Agents, Tricyclic/pharmacokineticsAntidepressive Agents, Tricyclic/therapeutic useAzabicyclo CompoundsCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme System/metabolismDepression/drug therapyDrug Therapy, CombinationHumansIsoenzymes/antagonists & inhibitorsIsoenzymes/metabolismMaleMianserin/adverse effectsMianserin/analogs & derivativesMianserin/pharmacokineticsMianserin/therapeutic useMirtazapinePiperazines/therapeutic useRestless Legs Syndrome/chemically inducedValproic Acid/analogs & derivativesValproic Acid/pharmacokineticsValproic Acid/therapeutic use
Substances: See more » Adrenergic alpha-2 Receptor AgonistsAdrenergic alpha-AgonistsAntidepressive Agents, TricyclicAzabicyclo CompoundsCytochrome P-450 Enzyme InhibitorsIsoenzymesPiperazineszopicloneMianserinValproic AcidCytochrome P-450 Enzyme SystemMirtazapinedipropylacetamide
Year: 2000 PMID: 11201984
Source DB: PubMed Journal: Therapie ISSN: 0040-5957 Impact factor: 2.070